1. Accueil >
  2. Zealand Pharma A/S convenes an extraordinary general meeting 2017 >
Nasdaq

Zealand Pharma A/S convenes an extraordinary general meeting 2017

07-07-2017

Zealand Pharma A/S indkalder til ekstraordinær generalforsamling 2017


Zealand Pharma A/S convenes an extraordinary general meeting 2017

Indkaldelse


til


ekstraordinær generalforsamling


i Zealand Pharma A/S


(CVR-nr. 20 04 50 78)


("Selskabet") 		  Notice


to convene


an extraordinary general meeting


  of Zealand Pharma A/S


(CVR no. 20 04 50 78)


("the Company")


Selskabets bestyrelse indkalder hermed til ekstraordinær generalforsamling i Selskabet, der afholdes    The board of directors of the Company hereby convenes an extraordinary general meeting of the Company, to be held on:
     
mandag, 31. juli 2017 kl. 8.00   Monday 31 July 2017 at 8.00 am CET
     
hos Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 København Ø.   at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark.
     
Dagsorden:   Agenda:
     
  1. Forslag fra bestyrelsen om vedtagelse af ny bemyndigelse til at forhøje Selskabets aktiekapital samt ændring af vedtægterne i overensstemmelse hermed
  
  1. Proposal from the board of directors to approve a new authorization to increase the Company's share capital and to amend the articles of association accordingly

 

  1. Forslag fra bestyrelsen om forhøjelse af den eksisterende bemyndigelse til forhøjelse af Selskabets aktiekapital i vedtægternes punkt 7
  
  1. Proposal by the board of directors to increase the existing authorization to increase the Company's share capital in article 7 of the articles of association
     
  1. Forslag fra bestyrelsen om at give Selskabets aktionærer ret til at udøve stemmerettigheder i tilknytning til nogle af deres aktier på en måde, der ikke er identisk med udøvelsen af stemmerettigheder i tilknytning til andre af deres aktier samt ændring af vedtægterne i overensstemmelse hermed
  
  1. Proposal by the board of directors to entitle the shareholders of the Company to exercise the voting rights attached to some of their shares in a manner that is not identical to the exercise of the voting rights attached to their other shares and to amend the articles of association accordingly
     
  1. Forslag fra bestyrelsen om at udvide den eksisterende bemyndigelse til Selskabet til erhvervelse af egne aktier til også at omfatte erhvervelse af American depositary shares


     
  2. Forslag fra bestyrelsen om skadesløsholdelse af bestyrelsen for visse krav i forbindelse med og efter Selskabets notering i USA

 




 




 



  1. Forslag fra bestyrelsen om vedtagelse af en bemyndigelse til bestyrelsen til at beslutte at lade Selskabet skadesløsholde direktionen samt Selskabets medarbejdere for visse krav i forbindelse med og efter Selskabets notering i USA og ændring af vedtægterne i overensstemmelse dermed

 




 

  1. Forslag fra bestyrelsen om opdatering af Selskabets overordnede retningslinjer for incitamentsaflønning


     
  2. Forslag fra bestyrelsen om, at alle dokumenter til brug for Selskabets generalforsamlinger i forbindelse med eller efter generalforsamlingen, herunder indkaldelsen og forhandlingsprotokollen, skal udarbejdes udelukkende på engelsk samt ændring af vedtægterne i overensstemmelse hermed
  
  1. Proposal by the board of directors to extend the existing authorization to the Company to acquire treasury shares to cover acquisitions of American depositary shares as well


     
  2. Proposal by the board of directors concerning the indemnification of the board of directors in relation to certain claims in connection with and after the listing of the Company in the United States


     
  3. Proposal by the board of directors to approve an authorization to the board of directors to resolve to let the Company idemnify the executive management as well as the Company's employees in relation to certain claims in connection with and after the listing of the Company in the United States and amendment of the articles of association accordingly


     
  4. Proposal by the board of directors to update the Company's Overall Guidelines for Incentive Pay


     
  5. Proposal by the board of directors that all documents prepared for use by or for a general meeting of the Company in connection with or after the general meeting, including the notice and the minutes, shall be prepared in English only and amendment of the articles of association accordingly
     
Ovenstående forslag 1, 3-6 og 8 fremsættes af Selskabets bestyrelse som led i Selskabets påtænkte udbud i USA af værdipapirer, der repræsenterer Selskabets aktier (sådanne værdipapirer er benævnt som American depositary shares eller ADS'er) og disses optagelse til handel på NASDAQ Global Select Market i USA, med de primære formål (i) at rejse kapital for at fremme Selskabets portefølje af lægemidler i udviklingsfasen og (ii) at udvide og sprede Selskabet's aktionærgruppe til at omfatte institutionelle og andre investorer hjemmehørende i USA. Bestyrelsen har endnu ikke besluttet, om man vil gå videre med dette udbud, men hvis generalforsamlingen autoriserer bestyrelsen til at forhøje Selskabets aktiekapital, vil bestyrelsen have fleksibilitet til at beslutte timing, antal ADS'er, antal underliggende aktier i Selskabet samt prisen i det foreslåede udbud. Selv hvis bestyrelsen beslutter at gå videre med det foreslåede udbud, er det ikke sikkert, at udbuddet vil blive gennemført.  




  		  The above proposals 1, 3-6 and 8 are submitted by the Company's board of directors as part of the contemplated offering by the Company in the United States of securities representing its ordinary shares (which securities are referred to as American depositary shares or ADSs) and admission thereof to trading on the NASDAQ Global Select Market in the United States, the purposes of which would primarily be: (i) to raise capital to advance the Company's proprietary drug pipeline, and (ii) to expand and diversify the Company's shareholder base to include U.S.-based institutional and other investors. The board of directors has not yet determined whether to proceed with this offering, but should the extraordinary general meeting authorize the board of directors to increase the Company's share capital, the board of directors will have the flexibility to determine the timing, number of ADSs, number of underlying shares of the Company and the price of the proposed offering. Even if the board of directors determines to proceed with the proposed offering, the offering may not be consummated.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via GlobeNewswire

HUG#2118798